ArticleJournal of gastrointestinal oncology2023

Second-line and third-line therapy with nanoliposomal irinotecan (nal-IRI) in pancreatic cancer: a single-center experience and review of literature.

Christian Möhring et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.